93 related articles for article (PubMed ID: 22284262)
1. Initiation treatment with imiglucerase every 3 weeks in type 1 Gaucher disease.
Serratrice C; Swiader L; Serratrice J; Weiller PJ; Verrot D
Eur J Intern Med; 2012 Mar; 23(2):e71-2. PubMed ID: 22284262
[No Abstract] [Full Text] [Related]
2. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
[TBL] [Abstract][Full Text] [Related]
4. Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease.
Elstein D; Abrahamov A; Hadas-Halpern I; Meyer A; Zimran A
QJM; 1998 Jul; 91(7):483-8. PubMed ID: 9797931
[TBL] [Abstract][Full Text] [Related]
5. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
Andersson H; Kaplan P; Kacena K; Yee J
Pediatrics; 2008 Dec; 122(6):1182-90. PubMed ID: 19047232
[TBL] [Abstract][Full Text] [Related]
6. Gaucher disease with pulmonary involvement in a 6-year-old girl: report of resolution of radiographic abnormalities on increasing dose of imiglucerase.
Lee SY; Mak AW; Huen KF; Lam ST; Chow CB
J Pediatr; 2001 Dec; 139(6):862-4. PubMed ID: 11743514
[TBL] [Abstract][Full Text] [Related]
7. Effective desensitization to imiglucerase in a patient with type I Gaucher disease.
Peroni DG; Pescollderungg L; Piacentini GL; Cassar W; Boner AL
J Pediatr; 2009 Dec; 155(6):940-1. PubMed ID: 19914435
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Gaucher's disease.
Barton NW; Brady RO; Dambrosia JM
N Engl J Med; 1993 May; 328(21):1564-5; author reply 1567-8. PubMed ID: 8479496
[No Abstract] [Full Text] [Related]
9. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase.
Weinreb N; Taylor J; Cox T; Yee J; vom Dahl S
Am J Hematol; 2008 Dec; 83(12):890-5. PubMed ID: 18819093
[TBL] [Abstract][Full Text] [Related]
10. The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy.
Wilson C; Spearing R; Teague L; Robertson P; Blacklock H
Mol Genet Metab; 2007; 92(1-2):131-6. PubMed ID: 17604204
[TBL] [Abstract][Full Text] [Related]
11. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
12. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
13. [Gaucher disease with multiple bone necrosis treated by enzyme replacement therapy and pamidronate].
Abe M; Minoguchi M; Jinbo J; Kikuchi Y; Chiba A; Shibata Y; Kogo Y
Nihon Naika Gakkai Zasshi; 2004 Nov; 93(11):2421-3. PubMed ID: 15624481
[No Abstract] [Full Text] [Related]
14. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
Altarescu G; Schiffmann R; Parker CC; Moore DF; Kreps C; Brady RO; Barton NW
Blood Cells Mol Dis; 2000 Aug; 26(4):285-90. PubMed ID: 11042029
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and therapy of Gaucher disease].
Ehlen C; Heintges T; Niederau C
Med Klin (Munich); 1995 May; 90(5):284-90. PubMed ID: 7791695
[TBL] [Abstract][Full Text] [Related]
16. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1.
Grabowski GA; Kacena K; Cole JA; Hollak CE; Zhang L; Yee J; Mistry PK; Zimran A; Charrow J; vom Dahl S
Genet Med; 2009 Feb; 11(2):92-100. PubMed ID: 19265748
[TBL] [Abstract][Full Text] [Related]
17. Treatment regimens in Gaucher's disease.
Beutler E
Lancet; 1995 Aug; 346(8974):581-2. PubMed ID: 7658807
[No Abstract] [Full Text] [Related]
18. Imiglucerase treatment in Gaucher's disease.
Shah U; Nadeem N; Husen Y; Fadoo Z
J Ayub Med Coll Abbottabad; 2007; 19(2):56-9. PubMed ID: 18183722
[TBL] [Abstract][Full Text] [Related]
19. Reduction in imiglucerase dosage causes immediate rise of chitotriosidase activity in patients with Gaucher disease.
Chien YH; Lee NC; Tsai FJ; Chao MC; Hwu WL
Mol Genet Metab; 2010 Sep; 101(1):90-1. PubMed ID: 20580583
[No Abstract] [Full Text] [Related]
20. Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1.
Pérez-Calvo J; Giraldo P; Pastores GM; Fernández-Galán M; Martín-Nuñez G; Pocoví M
J Postgrad Med; 2003; 49(2):127-31. PubMed ID: 12867687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
